DecisionDx-SCC How It Works | Castle Biosciences

Informs risk appropriate patient management

DecisionDx-SCC is a qRT-PCR assay of 6 control and 34 discriminant genes (40 in total) that uses a validated, proprietary neural network algorithm comprised of two gene expression signatures to classify patients into risk categories. The more personalized risk stratification or prognosis helps guide the most appropriate and individualized care for patients with SCC.

More biological insight, more appropriate patient management

Assesses:

40 genes
34 discriminating and 6 endogenous control genes

Provides:

Precise, personalized risk of metastasis and likelihood to benefit from adjuvant radiation therapy to better inform patient management decisions

Informs:

Patient management decisions including appropriateness of adjuvant radiation therapy, imaging, and frequency of surveillance

DecisionDx-SCC testing process

DecisionDx-SCC is performed in Castle Biosciences’ CLIA certified, CAP-accredited and NY state approved laboratory using formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision.

Tissue biopsy submitted

Tissue blocks or slides from the primary tumor tissue biopsies are sent to our laboratory for testing.

RNA/DNA preparation

Once tissue is received in our laboratory, RNA is isolated from the tissue and converted to cDNA. The cDNA for each of the 40 genes is amplified and the gene signature recorded.